The collaboration will work for the improvement, diagnosis and awareness of HCV infection in developed and emerging markets.
The researchers of Merck and Roche are expected to investigate the combinations of marketed and experimental medicines of both the parties to speed up the the availability of potential new treatment regimens for patients with HCV.
As per the terms of the agreement, Roche will promote Victrelis (boceprevir) to physicians as part of a triple combination therapy regimen, starting with the US, and Merck and Roche will work together to educate physicians and patients about hepatitis C, including diagnosis.
The companies will also work together to extend the agreement to other developed and emerging markets globally.
Merck Global Human Health executive vice president and president Adam Schechter said by working together they will be able to provide physicians, nurses and patients with education about the disease, its diagnosis and treatment options including the appropriate use of Victrelis.
Roche Pharmaceuticals Division chief operating officer Pascal Soriot said Roche will work with Merck to provide health care professionals and patients with education about the management of hepatitis C.
"Both companies will also collaborate to develop improved therapies for this serious disease," Soriot said.